NCT02619682View on ClinicalTrials.gov

Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 30, 2015

Primary Completion Date

June 1, 2022

Study Completion Date

October 31, 2025

Conditions
Plasma Cell MyelomaTransplant-Related Carcinoma
Interventions
DRUG

Ixazomib Citrate

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Lenalidomide

Given PO

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center, Seattle

All Listed Sponsors
lead

Fred Hutchinson Cancer Center

OTHER

NCT02619682 - Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma | Biotech Hunter | Biotech Hunter